Brief: Galapagos Announces Start Of Phase 2 Study With Selective TYK2 Inhibitor, GLPG3667
23/05/2023 22:25
May 23 (Reuters) - Galapagos NV GLPG.AS :
* GALAPAGOS ANNOUNCES START OF PHASE 2 STUDY WITH SELECTIVE
TYK2
INHIBITOR, GLPG3667, IN PATIENTS WITH DERMATOMYOSITIS
Source text for Eikon: ID:nGNX4LXM2X
Further company coverage: GLPG.AS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lakefront Biotherapeutics NV
See all newsBrief: Lakefront Announces Sale Of Preclinical Car-T Programs To Armed Cell Therapeutics
RBC upgrades Lakefront Biotherapeutics to 'outperform' on gamgertamig prospect
Brief: U.S. FDA Grants Orphan Drug Designation To Gamgertamig For The Treatment Of Pemphigus
Brief: Lakefront Biotherapeutics H1 Net Profit From Continuing Operations €15.8 Mln
Brief: Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline